Corrigendum

Corrigendum to “Expression of TRPC6 in benign and malignant human prostate tissues” by Dan Yue et al.

Dan Yue1, Yong Wang2, Jian-Ying Xiao1, Ping Wang2, Chang-Shan Ren1

1Cancer Research Institute, First Affiliated Hospital, China Medical University, Shenyang 110001, China
2Departments of Urology, Fourth Affiliated Hospital, China Medical University, Shenyang 110032, China
3Department of Biochemistry, Liaoning Medical University, Jinzhou 121001, China


Correspondence to: Dr Chang-Shan Ren, Cancer Research Institute, First Affiliated Hospital, China Medical University, Shenyang 110001, China.
Fax: +86-24-2326-8468 E-mail: csrencmu@yahoo.com.cn
Received: 26 October 2009 Accepted: 5 November 2009

In published paper by Dan Yue et al. [1], the Table 4 in page 545 was inadvertently misrepresented. The correct number and percentage of TRPC6 positive in BPH should be 9 (45.0). Now, the correct representation of Table 4 should be:

Table 4. Relationship between androgen responsiveness of tumor and TRPC6 protein.

<table>
<thead>
<tr>
<th>Androgen responsiveness</th>
<th>n</th>
<th>Evaluable specimens</th>
<th>TRPC6 positive (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BPH</td>
<td>20</td>
<td>20</td>
<td>9 (45.0)</td>
</tr>
<tr>
<td>AD</td>
<td>102</td>
<td>99</td>
<td>82 (82.8)</td>
</tr>
<tr>
<td>AI</td>
<td>34</td>
<td>33</td>
<td>29 (87.9)</td>
</tr>
</tbody>
</table>

Abbreviations: AD, androgen-dependent; AI, androgen-independent; BPH, benign prostatic hyperplasia; TRPC6, transient receptor potential canonical 6.

The authors would offer the profoundest apologies to the readers for any confusion and misunderstanding due to our careless and errors.

Reference